Components:
Method of action:
Treatment option:
Medically reviewed by Kovalenko Svetlana Olegovna, PharmD. Last updated on 04.04.2022
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
Top 20 medicines with the same components:
Top 20 medicines with the same treatments:
Dosage Forms And Strengths
XELODA is supplied as biconvex, oblong film-coated tablets for oral administration. Each light peachcolored tablet contains 150 mg of capecitabine and each peach-colored tablet contains 500 mg of capecitabine.
Storage And Handling
150 mg
Color: Light peach
Engraving: XELODA on one side and 150 on the other
150 mg tablets are packaged in bottles of 60 (NDC 0004-1100-20).
500 mg
Color: Peach
Engraving: XELODA on one side and 500 on the other
500 mg tablets are packaged in bottles of 120 (NDC 0004-1101-50).
Storage
Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F).. KEEP TIGHTLY CLOSED.
Care should be exercised in the handling of XELODA. XELODA tablets should not be cut or crushed. Procedures for the proper handling and disposal of anticancer drugs should be considered. Any unused product should be disposed of in accordance with local requirements, or drug take back programs. Several guidelines on the subject have been published.
REFERENCES
1. NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165.
2. OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html
3. American Society of Health-System Pharmacists. ASHP Guidelines on Handling Hazardous Drugs: Am J Health-Syst Pharm. 2006;63:1172-1193.
4. Polovich M., White JM, Kelleher LO (eds). Chemotherapy and biotherapy guidelines and recommendations for practice (2nd ed.) 2005. Pittsburgh, PA: Oncology Nursing Society.
Distributed by: Genentech USA, Inc. A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080-4990. Revised: Mar 2015
Colorectal Cancer
- XELODA is indicated as a single agent for adjuvant treatment in patients with Dukes' C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. XELODA was non-inferior to 5-fluorouracil and leucovorin (5-FU/LV) for disease-free survival (DFS). Physicians should consider results of combination chemotherapy trials, which have shown improvement in DFS and OS, when prescribing single-agent XELODA in the adjuvant treatment of Dukes' C colon cancer.
- XELODA is indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. Combination chemotherapy has shown a survival benefit compared to 5-FU/LV alone. A survival benefit over 5-FU/LV has not been demonstrated with XELODA monotherapy. Use of XELODA instead of 5-FU/LV in combinations has not been adequately studied to assure safety or preservation of the survival advantage.
Breast Cancer
- XELODA in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.
- XELODA monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated (e.g., patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents). Resistance is defined as progressive disease while on treatment, with or without an initial response, or relapse within 6 months of completing treatment with an anthracycline-containing adjuvant regimen.
XELODA tablets should be swallowed whole with water within 30 minutes after a meal. Do not crush or cut XELODA tablets. XELODA dose is calculated according to body surface area.
Standard Starting Dose
Monotherapy (Metastatic Colorectal Cancer, Adjuvant Colorectal Cancer, Metastatic Breast Cancer)
The recommended dose of XELODA is 1250 mg/m2 administered orally twice daily (morning and evening; equivalent to 2500 mg/m2 total daily dose) for 2 weeks followed by a 1-week rest period given as 3-week cycles (see Table 1).
Adjuvant treatment in patients with Dukes' C colon cancer is recommended for a total of 6 months [ie, XELODA 1250 mg/m2 orally twice daily for 2 weeks followed by a 1-week rest period, given as 3- week cycles for a total of 8 cycles (24 weeks)].
Table 1 XELODA Dose Calculation According to Body Surface Area
Dose Level 1250 mg/m2 Twice a Day | Number of Tablets to be Taken at Each Dose (Morning and Evening) | ||
Surface Area (m2) | Total Daily Dose* (mg) | 150 mg | 500 mg |
= 1.25 | 3000 | 0 | 3 |
1.26-1.37 | 3300 | 1 | 3 |
1.38-1.51 | 3600 | 2 | 3 |
1.52-1.65 | 4000 | 0 | 4 |
1.66-1.77 | 4300 | 1 | 4 |
1.78-1.91 | 4600 | 2 | 4 |
1.92-2.05 | 5000 | 0 | 5 |
2.06-2.17 | 5300 | 1 | 5 |
= 2.18 | 5600 | 2 | 5 |
*Total Daily Dose divided by 2 to allow equal morning and evening doses |
In Combination With Docetaxel (Metastatic Breast Cancer)
In combination with docetaxel, the recommended dose of XELODA is 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period, combined with docetaxel at 75 mg/m2 as a 1-hour intravenous infusion every 3 weeks. Pre-medication, according to the docetaxel labeling, should be started prior to docetaxel administration for patients receiving the XELODA plus docetaxel combination. Table 1 displays the total daily dose of XELODA by body surface area and the number of tablets to be taken at each dose.
Dose Management Guidelines
General
XELODA dosage may need to be individualized to optimize patient management. Patients should be carefully monitored for toxicity and doses of XELODA should be modified as necessary to accommodate individual patient tolerance to treatment. Toxicity due to XELODA administration may be managed by symptomatic treatment, dose interruptions and adjustment of XELODA dose. Once the dose has been reduced, it should not be increased at a later time. Doses of XELODA omitted for toxicity are not replaced or restored; instead the patient should resume the planned treatment cycles.
The dose of phenytoin and the dose of coumarin-derivative anticoagulants may need to be reduced when either drug is administered concomitantly with XELODA.
Monotherapy (Metastatic Colorectal Cancer, Adjuvant Colorectal Cancer, Metastatic Breast Cancer)
XELODA dose modification scheme as described below (see Table 2) is recommended for the management of adverse reactions.
Table 2 Recommended Dose Modifications of XELODA
Toxicity NCIC Grades* | During a Course of Therapy | Dose Adjustment for Next Treatment (% of starting dose) |
Grade 1 | Maintain dose level | Maintain dose level |
Grade 2 | ||
-1st appearance | Interrupt until resolved to grade 0-1 | 100% |
-2nd appearance | 75% | |
-3rd appearance | 50% | |
-4th appearance | Discontinue treatment permanently | - |
Grade 3 | ||
-1st appearance | Interrupt until resolved to grade 0-1 | 75% |
-2nd appearance | 50% | |
-3rd appearance | Discontinue treatment permanently | - |
Grade 4 | ||
-1st appearance | Discontinue permanently OR If physician deems it to be in the patient's best interest to continue, interrupt until resolved to grade 0-1 | 50% |
*National Cancer Institute of Canada Common Toxicity Criteria were used except for the hand-and-foot syndrome. |
In Combination With Docetaxel (Metastatic Breast Cancer)
Dose modifications of XELODA for toxicity should be made according to Table 2 above for XELODA. At the beginning of a treatment cycle, if a treatment delay is indicated for either XELODA or docetaxel, then administration of both agents should be delayed until the requirements for restarting both drugs are met.
The dose reduction schedule for docetaxel when used in combination with XELODA for the treatment of metastatic breast cancer is shown in Table 3.
Table 3 Docetaxel Dose Reduction Schedule in Combination with
XELODA
Toxicity NCIC Grades* | Grade 2 | Grade 3 | Grade 4 |
1st appearance | Delay treatment until resolved to grade 0-1; Resume treatment with original dose of 75 mg/m2 docetaxel | Delay treatment until resolved to grade 0-1; Resume treatment at 55 mg/m22 of docetaxel. | Discontinue treatment with docetaxel |
2nd appearance | Delay treatment until resolved to grade 0-1; Resume treatment at 55 mg/m2 of docetaxel. | Discontinue treatment with docetaxel | - |
3rd appearance | Discontinue treatment with docetaxel | - | - |
*National Cancer Institute of Canada Common Toxicity Criteria were used except for hand-and-foot syndrome. |
Adjustment Of Starting Dose In Special Populations
Renal Impairment
No adjustment to the starting dose of XELODA is recommended in patients with mild renal impairment (creatinine clearance = 51 to 80 mL/min [Cockroft and Gault, as shown below]). In patients with moderate renal impairment (baseline creatinine clearance = 30 to 50 mL/min), a dose reduction to 75% of the XELODA starting dose when used as monotherapy or in combination with docetaxel (from 1250 mg/m2 to 950 mg/m2 twice daily) is recommended. Subsequent dose adjustment is recommended as outlined in Table 2 and Table 3 (depending on the regimen) if a patient develops a grade 2 to 4 adverse event. The starting dose adjustment recommendations for patients with moderate renal impairment apply to both XELODA monotherapy and XELODA in combination use with docetaxel.
Cockroft and Gault Equation:
Males: | (weight in kg) x (140 – age) |
(72) x serum creatinine (mg/100 mL) | |
Females: | (0.85) x (above value) |
Geriatrics
Physicians should exercise caution in monitoring the effects of XELODA in the elderly. Insufficient data are available to provide a dosage recommendation.
Severe Renal Impairment
XELODA is contraindicated in patients with severe renal impairment (creatinine clearance below 30 mL/min [Cockroft and Gault]).
Hypersensitivity
XELODA is contraindicated in patients with known hypersensitivity to capecitabine or to any of its components. XELODA is contraindicated in patients who have a known hypersensitivity to 5- fluorouracil.
WARNINGS
Included as part of the "PRECAUTIONS" Section
PRECAUTIONS
General
Patients receiving therapy with XELODA should be monitored by a physician experienced in the use of cancer chemotherapeutic agents. Most adverse reactions are reversible and do not need to result in discontinuation, although doses may need to be withheld or reduced.
Coagulopathy
Patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy should have their anticoagulant response (INR or prothrombin time) monitored closely with great frequency and the anticoagulant dose should be adjusted accordingly.
Diarrhea
XELODA can induce diarrhea, sometimes severe. Patients with severe diarrhea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated. In 875 patients with either metastatic breast or colorectal cancer who received XELODA monotherapy, the median time to first occurrence of grade 2 to 4 diarrhea was 34 days (range from 1 to 369 days). The median duration of grade 3 to 4 diarrhea was 5 days. National Cancer Institute of Canada (NCIC) grade 2 diarrhea is defined as an increase of 4 to 6 stools/day or nocturnal stools, grade 3 diarrhea as an increase of 7 to 9 stools/day or incontinence and malabsorption, and grade 4 diarrhea as an increase of =10 stools/day or grossly bloody diarrhea or the need for parenteral support. If grade 2, 3 or 4 diarrhea occurs, administration of XELODA should be immediately interrupted until the diarrhea resolves or decreases in intensity to grade 1. Standard antidiarrheal treatments (eg, loperamide) are recommended.
Necrotizing enterocolitis (typhlitis) has been reported.
Cardiotoxicity
The cardiotoxicity observed with XELODA includes myocardial infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac failure, sudden death, electrocardiographic changes, and cardiomyopathy. These adverse reactions may be more common in patients with a prior history of coronary artery disease.
Dihydropyrimidine Dehydrogenase Deficiency
Based on postmarketing reports, patients with certain homozygous or certain compound heterozygous mutations in the DPD gene that result in complete or near complete absence of DPD activity are at increased risk for acute early-onset of toxicity and severe, life-threatening, or fatal adverse reactions caused by XELODA (e.g., mucositis, diarrhea, neutropenia, and neurotoxicity). Patients with partial DPD activity may also have increased risk of severe, life-threatening, or fatal adverse reactions caused by XELODA.
Withhold or permanently discontinue XELODA based on clinical assessment of the onset, duration and severity of the observed toxicities in patients with evidence of acute early-onset or unusually severe toxicity, which may indicate near complete or total absence of DPD activity. No XELODA dose has been proven safe for patients with complete absence of DPD activity. There is insufficient data to recommend a specific dose in patients with partial DPD activity as measured by any specific test.
Dehydration And Renal Failure
Dehydration has been observed and may cause acute renal failure which can be fatal. Patients with preexisting compromised renal function or who are receiving concomitant XELODA with known nephrotoxic agents are at higher risk. Patients with anorexia, asthenia, nausea, vomiting or diarrhea may rapidly become dehydrated. Monitor patients when XELODA is administered to prevent and correct dehydration at the onset. If grade 2 (or higher) dehydration occurs, XELODA treatment should be immediately interrupted and the dehydration corrected. Treatment should not be restarted until the patient is rehydrated and any precipitating causes have been corrected or controlled. Dose modifications should be applied for the precipitating adverse event as necessary.
Patients with moderate renal impairment at baseline require dose reduction. Patients with mild and moderate renal impairment at baseline should be carefully monitored for adverse reactions. Prompt interruption of therapy with subsequent dose adjustments is recommended if a patient develops a grade 2 to 4 adverse event as outlined in Table 2.
Pregnancy
XELODA may cause fetal harm when given to a pregnant woman. Capecitabine caused embryolethality and teratogenicity in mice and embryolethality in monkeys when administered during organogenesis. If this drug is used during pregnancy, or if a patient becomes pregnant while receiving XELODA, the patient should be apprised of the potential hazard to the fetus.
Mucocutaneous And Dermatologic Toxicity
Severe mucocutaneous reactions, some with fatal outcome, such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis (TEN) can occur in patients treated with XELODA. XELODA should be permanently discontinued in patients who experience a severe mucocutaneous reaction possibly attributable to XELODA treatment.
Hand-and-foot syndrome (palmar-plantar erythrodysesthesia or chemotherapy-induced acral erythema) is a cutaneous toxicity. Median time to onset was 79 days (range from 11 to 360 days) with a severity range of grades 1 to 3 for patients receiving XELODA monotherapy in the metastatic setting. Grade 1 is characterized by any of the following: numbness, dysesthesia/paresthesia, tingling, painless swelling or erythema of the hands and/or feet and/or discomfort which does not disrupt normal activities. Grade 2 hand-and-foot syndrome is defined as painful erythema and swelling of the hands and/or feet and/or discomfort affecting the patient's activities of daily living. Grade 3 hand-and-foot syndrome is defined as moist desquamation, ulceration, blistering or severe pain of the hands and/or feet and/or severe discomfort that causes the patient to be unable to work or perform activities of daily living. If grade 2 or 3 hand-and-foot syndrome occurs, administration of XELODA should be interrupted until the event resolves or decreases in intensity to grade 1. Following grade 3 hand-and-foot syndrome, subsequent doses of XELODA should be decreased.
Hyperbilirubinemia
In 875 patients with either metastatic breast or colorectal cancer who received at least one dose of XELODA 1250 mg/m2 twice daily as monotherapy for 2 weeks followed by a 1-week rest period, grade 3 (1.5-3 × ULN) hyperbilirubinemia occurred in 15.2% (n=133) of patients and grade 4 (>3 × ULN) hyperbilirubinemia occurred in 3.9% (n=34) of patients. Of 566 patients who had hepatic metastases at baseline and 309 patients without hepatic metastases at baseline, grade 3 or 4 hyperbilirubinemia occurred in 22.8% and 12.3%, respectively. Of the 167 patients with grade 3 or 4 hyperbilirubinemia, 18.6% (n=31) also had postbaseline elevations (grades 1 to 4, without elevations at baseline) in alkaline phosphatase and 27.5% (n=46) had postbaseline elevations in transaminases at any time (not necessarily concurrent). The majority of these patients, 64.5% (n=20) and 71.7% (n=33), had liver metastases at baseline. In addition, 57.5% (n=96) and 35.3% (n=59) of the 167 patients had elevations (grades 1 to 4) at both prebaseline and postbaseline in alkaline phosphatase or transaminases, respectively. Only 7.8% (n=13) and 3.0% (n=5) had grade 3 or 4 elevations in alkaline phosphatase or transaminases.
In the 596 patients treated with XELODA as first-line therapy for metastatic colorectal cancer, the incidence of grade 3 or 4 hyperbilirubinemia was similar to the overall clinical trial safety database of XELODA monotherapy. The median time to onset for grade 3 or 4 hyperbilirubinemia in the colorectal cancer population was 64 days and median total bilirubin increased from 8 µm/L at baseline to 13 µm/L during treatment with XELODA. Of the 136 colorectal cancer patients with grade 3 or 4 hyperbilirubinemia, 49 patients had grade 3 or 4 hyperbilirubinemia as their last measured value, of which 46 had liver metastases at baseline.
In 251 patients with metastatic breast cancer who received a combination of XELODA and docetaxel, grade 3 (1.5 to 3 × ULN) hyperbilirubinemia occurred in 7% (n=17) and grade 4 (>3 × ULN) hyperbilirubinemia occurred in 2% (n=5).
If drug-related grade 3 to 4 elevations in bilirubin occur, administration of XELODA should be immediately interrupted until the hyperbilirubinemia decreases to =3.0 × ULN.
Hematologic
In 875 patients with either metastatic breast or colorectal cancer who received a dose of 1250 mg/m2 administered twice daily as monotherapy for 2 weeks followed by a 1-week rest period, 3.2%, 1.7%, and 2.4% of patients had grade 3 or 4 neutropenia, thrombocytopenia or decreases in hemoglobin, respectively. In 251 patients with metastatic breast cancer who received a dose of XELODA in combination with docetaxel, 68% had grade 3 or 4 neutropenia, 2.8% had grade 3 or 4 thrombocytopenia, and 9.6% had grade 3 or 4 anemia.
Patients with baseline neutrophil counts of <1.5 × 10 /L and/or thrombocyte counts of <100 × 10 /L should not be treated with XELODA. If unscheduled laboratory assessments during a treatment cycle show grade 3 or 4 hematologic toxicity, treatment with XELODA should be interrupted.
Geriatric Patients
Patients =80 years old may experience a greater incidence of grade 3 or 4 adverse reactions. In 875 patients with either metastatic breast or colorectal cancer who received XELODA monotherapy, 62% of the 21 patients =80 years of age treated with XELODA experienced a treatment-related grade 3 or 4 adverse event: diarrhea in 6 (28.6%), nausea in 3 (14.3%), hand-and-foot syndrome in 3 (14.3%), and vomiting in 2 (9.5%) patients. Among the 10 patients 70 years of age and greater (no patients were >80 years of age) treated with XELODA in combination with docetaxel, 30% (3 out of 10) of patients experienced grade 3 or 4 diarrhea and stomatitis, and 40% (4 out of 10) experienced grade 3 hand-andfoot syndrome.
Among the 67 patients =60 years of age receiving XELODA in combination with docetaxel, the incidence of grade 3 or 4 treatment-related adverse reactions, treatment-related serious adverse reactions, withdrawals due to adverse reactions, treatment discontinuations due to adverse reactions and treatment discontinuations within the first two treatment cycles was higher than in the <60 years of age patient group.
In 995 patients receiving XELODA as adjuvant therapy for Dukes' C colon cancer after resection of the primary tumor, 41% of the 398 patients =65 years of age treated with XELODA experienced a treatment-related grade 3 or 4 adverse event: hand-and-foot syndrome in 75 (18.8%), diarrhea in 52 (13.1%), stomatitis in 12 (3.0%), neutropenia/granulocytopenia in 11 (2.8%), vomiting in 6 (1.5%), and nausea in 5 (1.3%) patients. In patients =65 years of age (all randomized population; capecitabine 188 patients, 5-FU/LV 208 patients) treated for Dukes' C colon cancer after resection of the primary tumor, the hazard ratios for disease-free survival and overall survival for XELODA compared to 5-FU/LV were 1.01 (95% C.I. 0.80 – 1.27) and 1.04 (95% C.I. 0.79 – 1.37), respectively.
Hepatic Insufficiency
Patients with mild to moderate hepatic dysfunction due to liver metastases should be carefully monitored when XELODA is administered. The effect of severe hepatic dysfunction on the disposition of XELODA is not known.
Combination With Other Drugs
Use of XELODA in combination with irinotecan has not been adequately studied.
Patient Counseling Information
Information for Patients (see FDA-approved Patient Labeling)
Patients and patients' caregivers should be informed of the expected adverse effects of XELODA, particularly nausea, vomiting, diarrhea, and hand-and-foot syndrome, and should be made aware that patient-specific dose adaptations during therapy are expected and necessary. As described below, patients taking XELODA should be informed of the need to interrupt treatment and to call their physician immediately if moderate or severe toxicity occurs. Patients should be encouraged to recognize the common grade 2 toxicities associated with XELODA treatment See FDA-approved patient labeling (Patient Information).
Dihydropyrimidine Dehydrogenase Deficiency
Patients should be advised to notify their healthcare provider if they have a known DPD deficiency. Advise patients if they have complete or near complete absence of DPD activity they are at an increased risk of acute early-onset of toxicity and severe, life-threatening, or fatal adverse reactions caused by XELODA (e.g., mucositis, diarrhea, neutropenia, and neurotoxicity).
Diarrhea
Patients experiencing grade 2 diarrhea (an increase of 4 to 6 stools/day or nocturnal stools) or greater or experiencing severe bloody diarrhea with severe abdominal pain and fever should be instructed to stop taking XELODA and to call their physician immediately. Standard antidiarrheal treatments (eg, loperamide) are recommended.
Dehydration
Patients experiencing grade 2 or higher dehydration should be instructed to stop taking XELODA immediately and the dehydration corrected. Treatment should not be restarted until the patient is rehydrated and any precipitating causes have been corrected or controlled.
Nausea
Patients experiencing grade 2 nausea (food intake significantly decreased but able to eat intermittently) or greater should be instructed to stop taking XELODA immediately. Initiation of symptomatic treatment is recommended.
Vomiting
Patients experiencing grade 2 vomiting (2 to 5 episodes in a 24-hour period) or greater should be instructed to stop taking XELODA immediately. Initiation of symptomatic treatment is recommended.
Hand-And-Foot Syndrome
Patients experiencing grade 2 hand-and-foot syndrome (painful erythema and swelling of the hands and/or feet and/or discomfort affecting the patients' activities of daily living) or greater should be instructed to stop taking XELODA immediately. Initiation of symptomatic treatment is recommended.
Stomatitis
Patients experiencing grade 2 stomatitis (painful erythema, edema or ulcers of the mouth or tongue, but able to eat) or greater should be instructed to stop taking XELODA immediately and to call their physician. Initiation of symptomatic treatment is recommended.
Fever And Neutropenia
Patients who develop a fever of 100.5°F or greater or other evidence of potential infection should be instructed to call their physician immediately.
Nonclinical Toxicology
Carcinogenesis, Mutagenesis, Impairment Of Fertility
Adequate studies investigating the carcinogenic potential of XELODA have not been conducted. Capecitabine was not mutagenic in vitro to bacteria (Ames test) or mammalian cells (Chinese hamster V79/HPRT gene mutation assay). Capecitabine was clastogenic in vitro to human peripheral blood lymphocytes but not clastogenic in vivo to mouse bone marrow (micronucleus test). Fluorouracil causes mutations in bacteria and yeast. Fluorouracil also causes chromosomal abnormalities in the mouse micronucleus test in vivo.
Impairment Of Fertility
In studies of fertility and general reproductive performance in female mice, oral capecitabine doses of 760 mg/kg/day (about 2300 mg/m2 /day) disturbed estrus and consequently caused a decrease in fertility. In mice that became pregnant, no fetuses survived this dose. The disturbance in estrus was reversible. In males, this dose caused degenerative changes in the testes, including decreases in the number of spermatocytes and spermatids. In separate pharmacokinetic studies, this dose in mice produced 5'-DFUR AUC values about 0.7 times the corresponding values in patients administered the recommended daily dose.
Use In Specific Populations
Pregnancy
Category D
XELODA can cause fetal harm when administered to a pregnant woman. Capecitabine at doses of 198 mg/kg/day during organogenesis caused malformations and embryo death in mice. In separate pharmacokinetic studies, this dose in mice produced 5'-DFUR AUC values about 0.2 times the corresponding values in patients administered the recommended daily dose. Malformations in mice included cleft palate, anophthalmia, microphthalmia, oligodactyly, polydactyly, syndactyly, kinky tail and dilation of cerebral ventricles. At doses of 90 mg/kg/day, capecitabine given to pregnant monkeys during organogenesis caused fetal death. This dose produced 5'-DFUR AUC values about 0.6 times the corresponding values in patients administered the recommended daily dose.
There are no adequate and well controlled studies of XELODA in pregnant women. If this drug is used during pregnancy, or if a patient becomes pregnant while receiving XELODA, the patient should be apprised of the potential hazard to the fetus. Women should be advised to avoid becoming pregnant while receiving treatment with XELODA.
Nursing Mothers
Lactating mice given a single oral dose of capecitabine excreted significant amounts of capecitabine metabolites into the milk. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from capecitabine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Pediatric Use
The safety and effectiveness of XELODA in pediatric patients have not been established. No clinical benefit was demonstrated in two single arm trials in pediatric patients with newly diagnosed brainstem gliomas and high grade gliomas. In both trials, pediatric patients received an investigational pediatric formulation of capecitabine concomitantly with and following completion of radiation therapy (total dose of 5580 cGy in 180 cGy fractions). The relative bioavailability of the investigational formulation to XELODA was similar.
The first trial was conducted in 22 pediatric patients (median age 8 years, range 5-17 years) with newly diagnosed non-disseminated intrinsic diffuse brainstem gliomas and high grade gliomas. In the dosefinding portion of the trial, patients received capecitabine with concomitant radiation therapy at doses ranging from 500 mg/m2 to 850 mg/m2 every 12 hours for up to 9 weeks. After a 2 week break, patients received 1250 mg/m2 capecitabine every 12 hours on Days 1-14 of a 21-day cycle for up to 3 cycles. The maximum tolerated dose (MTD) of capecitabine administered concomitantly with radiation therapy was 650 mg/m2 every 12 hours. The major dose limiting toxicities were palmar-plantar erythrodysesthesia and alanine aminotransferase (ALT) elevation.
The second trial was conducted in 34 additional pediatric patients with newly diagnosed nondisseminated intrinsic diffuse brainstem gliomas (median age 7 years, range 3-16 years) and 10 pediatric patients who received the MTD of capecitabine in the dose-finding trial and met the eligibility criteria for this trial. All patients received 650 mg/m2 capecitabine every 12 hours with concomitant radiation therapy for up to 9 weeks. After a 2 week break, patients received 1250 mg/m2 capecitabine every 12 hours on Days 1-14 of a 21-day cycle for up to 3 cycles.
There was no improvement in one-year progression-free survival rate and one-year overall survival rate in pediatric patients with newly diagnosed intrinsic brainstem gliomas who received capecitabine relative to a similar population of pediatric patients who participated in other clinical trials.
The adverse reaction profile of capecitabine was consistent with the known adverse reaction profile in adults, with the exception of laboratory abnormalities which occurred more commonly in pediatric patients. The most frequently reported laboratory abnormalities (per-patient incidence =40%) were increased ALT (75%), lymphocytopenia (73%), leukopenia (73%), hypokalemia (68%), thrombocytopenia (57%), hypoalbuminemia (55%), neutropenia (50%), low hematocrit (50%), hypocalcemia (48%), hypophosphatemia (45%) and hyponatremia (45%).
Geriatric Use
Physicians should pay particular attention to monitoring the adverse effects of XELODA in the elderly .
Hepatic Insufficiency
Exercise caution when patients with mild to moderate hepatic dysfunction due to liver metastases are treated with XELODA. The effect of severe hepatic dysfunction on XELODA is not known.
Renal Insufficiency
Patients with moderate (creatinine clearance = 30 to 50 mL/min) and severe (creatinine clearance <30 mL/min) renal impairment showed higher exposure for capecitabine, 5-DFUR, and FBAL than in those with normal renal function.
SIDE EFFECTS
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adjuvant Colon Cancer
Table 4 shows the adverse reactions occurring in =5% of patients from one phase 3 trial in patients with Dukes' C colon cancer who received at least one dose of study medication and had at least one safety assessment. A total of 995 patients were treated with 1250 mg/m2 twice a day of XELODA administered for 2 weeks followed by a 1-week rest period, and 974 patients were administered 5-FU and leucovorin (20 mg/m2 leucovorin IV followed by 425 mg/m2 IV bolus 5-FU on days 1-5 every 28 days). The median duration of treatment was 164 days for capecitabine-treated patients and 145 days for 5-FU/LV-treated patients. A total of 112 (11%) and 73 (7%) capecitabine and 5-FU/LV-treated patients, respectively, discontinued treatment because of adverse reactions. A total of 18 deaths due to all causes occurred either on study or within 28 days of receiving study drug: 8 (0.8%) patients randomized to XELODA and 10 (1.0%) randomized to 5-FU/LV.
Table 5 shows grade 3/4 laboratory abnormalities occurring in =1% of patients from one phase 3 trial in patients with Dukes' C colon cancer who received at least one dose of study medication and had at least one safety assessment.
Table 4 Percent Incidence of Adverse Reactions Reported in =5% of
Patients Treated With XELODA or 5-FU/LV for Colon Cancer in the
Adjuvant Setting (Safety Population)
Body System/ Adverse Event |
Adjuvant Treatment for Colon Cancer (N=1969) | |||
XELODA (N=995) | 5-FU/LV (N=974) | |||
All Grades | Grade 3/4 | All Grades | Grade 3/4 | |
Gastrointestinal Disorders | ||||
Diarrhea | 47 | 12 | 65 | 14 |
Nausea | 34 | 2 | 47 | 2 |
Stomatitis | 22 | 2 | 60 | 14 |
Vomiting | 15 | 2 | 21 | 2 |
Abdominal Pain | 14 | 3 | 16 | 2 |
Constipation | 9 | - | 11 | <1 |
Upper Abdominal Pain | 7 | <1 | 7 | <1 |
Dyspepsia | 6 | <1 | 5 | - |
Skin and Subcutaneous Tissue Disorders | ||||
Hand-and-Foot Syndrome | 60 | 17 | 9 | <1 |
Alopecia | 6 | - | 22 | <1 |
Rash | 7 | - | 8 | - |
Erythema | 6 | 1 | 5 | <1 |
General Disorders and Administration Site Conditions | ||||
Fatigue | 16 | <1 | 16 | 1 |
Pyrexia | 7 | <1 | 9 | <1 |
Asthenia | 10 | <1 | 10 | 1 |
Lethargy | 10 | <1 | 9 | <1 |
Nervous System Disorders | ||||
Dizziness | 6 | <1 | 6 | - |
Headache | 5 | <1 | 6 | <1 |
Dysgeusia | 6 | - | 9 | - |
Metabolism and Nutrition Disorders | ||||
Anorexia | 9 | <1 | 11 | <1 |
Eye Disorders | ||||
Conjunctivitis | 5 | <1 | 6 | <1 |
Blood and Lymphatic System Disorders | ||||
Neutropenia | 2 | <1 | 8 | 5 |
Respiratory Thoracic and Mediastinal Disorders | ||||
Epistaxis | 2 | - | 5 | - |
Table 5 Percent Incidence of Grade 3/4 Laboratory Abnormalities
Reported in =1% of Patients Receiving XELODA Monotherapy for
Adjuvant Treatment of Colon Cancer (Safety Population)
Advers e Event | XELODA (n=995) Grade 3/4 % | IV 5-FU/LV (n=974) Grade 3/4 % |
Increased ALAT (SGPT) | 1.6 | 0.6 |
Increased calcium | 1.1 | 0.7 |
Decreased calcium | 2.3 | 2.2 |
Decreased hemoglobin | 1.0 | 1.2 |
Decreased lymphocytes | 13.0 | 13.0 |
Decreased neutrophils* | 2.2 | 26.2 |
Decreased neutrophils/granulocytes | 2.4 | 26.4 |
Decreased platelets | 1.0 | 0.7 |
Increased bilirubin† | 20 | 6.3 |
*The incidence of grade 3/4 white blood cell abnormalities was 1.3% in the XELODA arm and 4.9% in the IV 5-FU/LV arm. †It should be noted that grading was according to NCIC CTC Version 1 (May, 1994 ). In the NCIC-CTC Version 1, hyperbilirubinemia grade 3 indicates a bilirubin value of 1.5 to 3.0 x upper limit of normal (ULN) range, and grade 4 a value of > 3.0 x ULN. The NCI CTC Version 2 and above define a grade 3 bilirubin value of>3.0 to 10.0 x ULN, and grade 4 values >10.0 x ULN. |
Metastatic Colorectal Cancer
Monotherapy
Table 6 shows the adverse reactions occurring in =5% of patients from pooling the two phase 3 trials in first line metastatic colorectal cancer. A total of 596 patients with metastatic colorectal cancer were treated with 1250 mg/m2 twice a day of XELODA administered for 2 weeks followed by a 1-week rest period, and 593 patients were administered 5-FU and leucovorin in the Mayo regimen (20 mg/m2 leucovorin IV followed by 425 mg/m2 IV bolus 5-FU, on days 1-5, every 28 days). In the pooled colorectal database the median duration of treatment was 139 days for capecitabine-treated patients and 140 days for 5-FU/LV-treated patients. A total of 78 (13%) and 63 (11%) capecitabine and 5-FU/LVtreated patients, respectively, discontinued treatment because of adverse reactions/intercurrent illness. A total of 82 deaths due to all causes occurred either on study or within 28 days of receiving study drug: 50 (8.4%) patients randomized to XELODA and 32 (5.4%) randomized to 5-FU/LV.
Table 6 Pooled Phase 3 Colorectal Trials : Percent Incidence of Adverse
Reactions in =5% of Patients
Adverse Event | XELODA (n=596) |
5-FU/LV (n=593) |
||||
Total % |
Grade 3% |
Grade 4% |
Total % |
Grade 3% |
Grade 4% |
|
Number of Patients With > One Adverse Event |
96 | 52 | 9 | 94 | 45 | 9 |
Body System/Adverse Event | ||||||
GI | ||||||
Diarrhea | 55 | 13 | 2 | 61 | 10 | 2 |
Nausea | 43 | 4 | - | 51 | 3 | <1 |
Vomiting | 27 | 4 | <1 | 30 | 4 | <1 |
Stomatitis | 25 | 2 | <1 | 62 | 14 | 1 |
Abdominal Pain | 35 | 9 | <1 | 31 | 5 | - |
Gastrointestinal Motility Disorder |
10 | <1 | - | 7 | <1 | - |
Constipation | 14 | 1 | <1 | 17 | 1 | - |
Oral Discomfort | 10 | - | - | 10 | - | - |
Upper GI Inflammatory Disorders |
8 | <1 | - | 10 | 1 | - |
Gastrointestinal Hemorrhage |
6 | 1 | <1 | 3 | 1 | - |
Ileus | 6 | 4 | 1 | 5 | 2 | 1 |
Skin and Subcutaneous | ||||||
Hand-and-Foot Syndrome |
54 | 17 | NA | 6 | 1 | NA |
Dermatitis | 27 | 1 | - | 26 | 1 | - |
Skin Discoloration | 7 | <1 | - | 5 | - | - |
Alopecia | 6 | - | - | 21 | <1 | - |
General | ||||||
Fatigue/Weakness | 42 | 4 | - | 46 | 4 | - |
Pyrexia | 18 | 1 | - | 21 | 2 | - |
Edema | 15 | 1 | - | 9 | 1 | - |
Pain | 12 | 1 | - | 10 | 1 | - |
Chest Pain | 6 | 1 | - | 6 | 1 | <1 |
Neurological | ||||||
Peripheral Sensory Neuropathy | 10 | - | - | 4 | - | - |
Headache | 10 | 1 | - | 7 | - | - |
Dizziness* | 8 | <1 | - | 8 | <1 | - |
Insomnia | 7 | - | - | 7 | - | - |
Taste Disturbance | 6 | 1 | - | 11 | <1 | 1 |
Metabolism | ||||||
Appetite Decreased | 26 | 3 | <1 | 31 | 2 | <1 |
Dehydration | 7 | 2 | <1 | 8 | 3 | 1 |
Eye | ||||||
Eye Irritation | 13 | - | - | 10 | <1 | - |
Vision Abnormal | 5 | - | - | 2 | - | - |
Respiratory | ||||||
Dyspnea | 14 | 1 | - | 10 | <1 | 1 |
Cough | 7 | <1 | 1 | 8 | - | - |
Pharyngeal Disorder | 5 | - | - | 5 | - | - |
Epistaxis | 3 | <1 | - | 6 | - | - |
Sore Throat | 2 | - | - | 6 | - | - |
Musculoskeletal | ||||||
Back Pain | 10 | 2 | - | 9 | <1 | - |
Arthralgia | 8 | 1 | - | 6 | 1 | - |
Vascular | ||||||
Venous Thrombosis | 8 | 3 | <1 | 6 | 2 | - |
Psychiatric | ||||||
Mood Alteration | 5 | - | - | 6 | <1 | - |
Depression | 5 | - | - | 4 | <1 | - |
Infections | ||||||
Viral | 5 | <1 | - | 5 | <1 | - |
Blood and Lymphatic | ||||||
Anemia | 80 | 2 | <1 | 79 | 1 | <1 |
Neutropenia | 13 | 1 | 2 | 46 | 8 | 13 |
Hepatobiliary | ||||||
Hyperbilirubinemia | 48 | 18 | 5 | 17 | 3 | 3 |
–Not observed NA = Not Applicable *Excluding vertigo |
Breast Cancer
In Combination With Docetaxel
The following data are shown for the combination study with XELODA and docetaxel in patients with metastatic breast cancer in Table 7 and Table 8. In the XELODA and docetaxel combination arm the treatment was XELODA administered orally 1250 mg/m2 twice daily as intermittent therapy (2 weeks of treatment followed by 1 week without treatment) for at least 6 weeks and docetaxel administered as a 1- hour intravenous infusion at a dose of 75 mg/m2 on the first day of each 3-week cycle for at least 6 weeks. In the monotherapy arm docetaxel was administered as a 1-hour intravenous infusion at a dose of 100 mg/m2 on the first day of each 3-week cycle for at least 6 weeks. The mean duration of treatment was 129 days in the combination arm and 98 days in the monotherapy arm. A total of 66 patients (26%) in the combination arm and 49 (19%) in the monotherapy arm withdrew from the study because of adverse reactions. The percentage of patients requiring dose reductions due to adverse reactions was 65% in the combination arm and 36% in the monotherapy arm. The percentage of patients requiring treatment interruptions due to adverse reactions in the combination arm was 79%. Treatment interruptions were part of the dose modification scheme for the combination therapy arm but not for the docetaxel monotherapy-treated patients.
Table 7 Percent Incidence of Adverse Events Considered Related or
Unrelated to Treatment in =5% of Patients Participating in the XELODA
and Docetaxel Combination vs Docetaxel Monotherapy Study
Adverse Event | XELODA 1250 mg/m2 /bid With Docetaxel 75 mg/m2 /3 weeks (n=251) |
Docetaxel 100 mg/m2 /3 weeks (n=255) |
||||
Total % |
Grade 3% |
Grade 4% |
Total % |
Grade 3% |
Grade 4% |
|
Number of Patients With at Least One Adverse Event |
99 | 76.5 | 29.1 | 97 | 57.6 | 31.8 |
Body System/Adverse Event | ||||||
GI | ||||||
Diarrhea | 67 | 14 | <1 | 48 | 5 | <1 |
Stomatitis | 67 | 17 | <1 | 43 | 5 | - |
Nausea | 45 | 7 | - | 36 | 2 | - |
Vomiting | 35 | 4 | 1 | 24 | 2 | - |
Constipation | 20 | 2 | - | 18 | - | - |
Abdominal Pain | 30 | <3 | <1 | 24 | 2 | - |
Dyspepsia | 14 | - | - | 8 | 1 | - |
Dry Mouth | 6 | <1 | - | 5 | - | - |
Skin and Subcutaneous | ||||||
Hand-and-Foot Syndrome |
63 | 24 | NA | 8 | 1 | NA |
Alopecia | 41 | 6 | - | 42 | 7 | - |
Nail Disorder | 14 | 2 | - | 15 | - | - |
Dermatitis | 8 | - | - | 11 | 1 | - |
Rash Erythematous | 9 | <1 | - | 5 | - | - |
Nail Discoloration | 6 | - | - | 4 | <1 | - |
Onycholysis | 5 | 1 | - | 5 | 1 | - |
Pruritus | 4 | - | - | 5 | - | - |
General | ||||||
Pyrexia | 28 | 2 | - | 34 | 2 | - |
Asthenia | 26 | 4 | <1 | 25 | 6 | - |
Fatigue | 22 | 4 | - | 27 | 6 | - |
Weakness | 16 | 2 | - | 11 | 2 | - |
Pain in Limb | 13 | <1 | - | 13 | 2 | - |
Lethargy | 7 | - | - | 6 | 2 | - |
Pain | 7 | <1 | - | 5 | 1 | - |
Chest Pain (non-cardiac) | 4 | <1 | - | 6 | 2 | - |
Influenza-like Illness | 5 | - | - | 5 | - | - |
Neurological | ||||||
Taste Disturbance | 16 | <1 | - | 14 | <1 | - |
Headache | 15 | 3 | - | 15 | 2 | - |
Paresthesia | 12 | <1 | - | 16 | 1 | - |
Dizziness | 12 | - | - | 8 | <1 | - |
Insomnia | 8 | - | - | 10 | <1 | - |
Peripheral Neuropathy | 6 | - | - | 10 | 1 | - |
Hypoaesthesia | 4 | <1 | - | 8 | <1 | - |
Metabolism | ||||||
Anorexia | 13 | 1 | - | 11 | <1 | - |
Appetite Decreased | 10 | - | - | 5 | - | - |
Weight Decreased | 7 | - | - | 5 | - | - |
Dehydration | 10 | 2 | - | 7 | <1 | <1 |
Eye | ||||||
Lacrimation Increased | 12 | - | - | 7 | <1 | - |
Conjunctivitis | 5 | - | - | 4 | - | - |
Eye Irritation | 5 | - | - | 1 | - | - |
Musculoskeletal | ||||||
Arthralgia | 15 | 2 | - | 24 | 3 | - |
Myalgia | 15 | 2 | - | 25 | 2 | - |
Back Pain | 12 | <1 | - | 11 | 3 | - |
Bone Pain | 8 | <1 | - | 10 | 2 | - |
Cardiac | ||||||
Edema | 33 | <2 | - | 34 | <3 | 1 |
Blood | ||||||
Neutropenic Fever | 16 | 3 | 13 | 21 | 5 | 16 |
Respiratory | ||||||
Dyspnea | 14 | 2 | <1 | 16 | 2 | - |
Cough | 13 | 1 | - | 22 | <1 | - |
Sore Throat | 12 | 2 | - | 11 | <1 | - |
Epistaxis | 7 | <1 | - | 6 | - | - |
Rhinorrhea | 5 | - | - | 3 | - | - |
Pleural Effusion | 2 | 1 | - | 7 | 4 | - |
Infections | ||||||
Oral Candidiasis | 7 | <1 | - | 8 | <1 | - |
Urinary Tract Infection | 6 | <1 | - | 4 | - | - |
Upper Respiratory Tract | 4 | - | - | 5 | 1 | - |
Vascular | ||||||
Flushing | 5 | - | - | 5 | - | - |
Lymphoedema | 3 | <1 | - | 5 | - | - |
Psychiatric | ||||||
Depression | 5 | - | - | 5 | 1 | - |
–Not observed NA = Not Applicable |
Table 8 Percent of Patients With Laboratory Abnormalities Participating
in the XELODA and Docetaxel Combination vs Docetaxel Monotherapy
Study
Adverse Event | XELODA 1250
mg/m2 /bid With Docetaxel 75 mg/m2 /3 weeks (n=251) |
Docetaxel
100 mg/m2 /3 weeks (n=255) |
||||
Body System/ Adverse Event |
Total % |
Grade
3 % |
Grade
4 % |
Total % |
Grade
3 % |
Grade
4 % |
Hematologic | ||||||
Leukopenia | 91 | 37 | 24 | 88 | 42 | 33 |
Neutropenia/ Granulocytopenia | 86 | 20 | 49 | 87 | 10 | 66 |
Thrombocytopenia | 41 | 2 | 1 | 23 | 1 | 2 |
Anemia | 80 | 7 | 3 | 83 | 5 | <1 |
Lymphocytopenia | 99 | 48 | 41 | 98 | 44 | 40 |
Hepatobiliary | ||||||
Hyperbilirubinemia | 20 | 7 | 2 | 6 | 2 | 2 |
Monotherapy
The following data are shown for the study in stage IV breast cancer patients wh
Category D
XELODA can cause fetal harm when administered to a pregnant woman. Capecitabine at doses of 198 mg/kg/day during organogenesis caused malformations and embryo death in mice. In separate pharmacokinetic studies, this dose in mice produced 5'-DFUR AUC values about 0.2 times the corresponding values in patients administered the recommended daily dose. Malformations in mice included cleft palate, anophthalmia, microphthalmia, oligodactyly, polydactyly, syndactyly, kinky tail and dilation of cerebral ventricles. At doses of 90 mg/kg/day, capecitabine given to pregnant monkeys during organogenesis caused fetal death. This dose produced 5'-DFUR AUC values about 0.6 times the corresponding values in patients administered the recommended daily dose.
There are no adequate and well controlled studies of XELODA in pregnant women. If this drug is used during pregnancy, or if a patient becomes pregnant while receiving XELODA, the patient should be apprised of the potential hazard to the fetus. Women should be advised to avoid becoming pregnant while receiving treatment with XELODA.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adjuvant Colon Cancer
Table 4 shows the adverse reactions occurring in =5% of patients from one phase 3 trial in patients with Dukes' C colon cancer who received at least one dose of study medication and had at least one safety assessment. A total of 995 patients were treated with 1250 mg/m2 twice a day of XELODA administered for 2 weeks followed by a 1-week rest period, and 974 patients were administered 5-FU and leucovorin (20 mg/m2 leucovorin IV followed by 425 mg/m2 IV bolus 5-FU on days 1-5 every 28 days). The median duration of treatment was 164 days for capecitabine-treated patients and 145 days for 5-FU/LV-treated patients. A total of 112 (11%) and 73 (7%) capecitabine and 5-FU/LV-treated patients, respectively, discontinued treatment because of adverse reactions. A total of 18 deaths due to all causes occurred either on study or within 28 days of receiving study drug: 8 (0.8%) patients randomized to XELODA and 10 (1.0%) randomized to 5-FU/LV.
Table 5 shows grade 3/4 laboratory abnormalities occurring in =1% of patients from one phase 3 trial in patients with Dukes' C colon cancer who received at least one dose of study medication and had at least one safety assessment.
Table 4 Percent Incidence of Adverse Reactions Reported in =5% of
Patients Treated With XELODA or 5-FU/LV for Colon Cancer in the
Adjuvant Setting (Safety Population)
Body System/ Adverse Event |
Adjuvant Treatment for Colon Cancer (N=1969) | |||
XELODA (N=995) | 5-FU/LV (N=974) | |||
All Grades | Grade 3/4 | All Grades | Grade 3/4 | |
Gastrointestinal Disorders | ||||
Diarrhea | 47 | 12 | 65 | 14 |
Nausea | 34 | 2 | 47 | 2 |
Stomatitis | 22 | 2 | 60 | 14 |
Vomiting | 15 | 2 | 21 | 2 |
Abdominal Pain | 14 | 3 | 16 | 2 |
Constipation | 9 | - | 11 | <1 |
Upper Abdominal Pain | 7 | <1 | 7 | <1 |
Dyspepsia | 6 | <1 | 5 | - |
Skin and Subcutaneous Tissue Disorders | ||||
Hand-and-Foot Syndrome | 60 | 17 | 9 | <1 |
Alopecia | 6 | - | 22 | <1 |
Rash | 7 | - | 8 | - |
Erythema | 6 | 1 | 5 | <1 |
General Disorders and Administration Site Conditions | ||||
Fatigue | 16 | <1 | 16 | 1 |
Pyrexia | 7 | <1 | 9 | <1 |
Asthenia | 10 | <1 | 10 | 1 |
Lethargy | 10 | <1 | 9 | <1 |
Nervous System Disorders | ||||
Dizziness | 6 | <1 | 6 | - |
Headache | 5 | <1 | 6 | <1 |
Dysgeusia | 6 | - | 9 | - |
Metabolism and Nutrition Disorders | ||||
Anorexia | 9 | <1 | 11 | <1 |
Eye Disorders | ||||
Conjunctivitis | 5 | <1 | 6 | <1 |
Blood and Lymphatic System Disorders | ||||
Neutropenia | 2 | <1 | 8 | 5 |
Respiratory Thoracic and Mediastinal Disorders | ||||
Epistaxis | 2 | - | 5 | - |
Table 5 Percent Incidence of Grade 3/4 Laboratory Abnormalities
Reported in =1% of Patients Receiving XELODA Monotherapy for
Adjuvant Treatment of Colon Cancer (Safety Population)
Advers e Event | XELODA (n=995) Grade 3/4 % | IV 5-FU/LV (n=974) Grade 3/4 % |
Increased ALAT (SGPT) | 1.6 | 0.6 |
Increased calcium | 1.1 | 0.7 |
Decreased calcium | 2.3 | 2.2 |
Decreased hemoglobin | 1.0 | 1.2 |
Decreased lymphocytes | 13.0 | 13.0 |
Decreased neutrophils* | 2.2 | 26.2 |
Decreased neutrophils/granulocytes | 2.4 | 26.4 |
Decreased platelets | 1.0 | 0.7 |
Increased bilirubin† | 20 | 6.3 |
*The incidence of grade 3/4 white blood cell abnormalities was 1.3% in the XELODA arm and 4.9% in the IV 5-FU/LV arm. †It should be noted that grading was according to NCIC CTC Version 1 (May, 1994 ). In the NCIC-CTC Version 1, hyperbilirubinemia grade 3 indicates a bilirubin value of 1.5 to 3.0 x upper limit of normal (ULN) range, and grade 4 a value of > 3.0 x ULN. The NCI CTC Version 2 and above define a grade 3 bilirubin value of>3.0 to 10.0 x ULN, and grade 4 values >10.0 x ULN. |
Metastatic Colorectal Cancer
Monotherapy
Table 6 shows the adverse reactions occurring in =5% of patients from pooling the two phase 3 trials in first line metastatic colorectal cancer. A total of 596 patients with metastatic colorectal cancer were treated with 1250 mg/m2 twice a day of XELODA administered for 2 weeks followed by a 1-week rest period, and 593 patients were administered 5-FU and leucovorin in the Mayo regimen (20 mg/m2 leucovorin IV followed by 425 mg/m2 IV bolus 5-FU, on days 1-5, every 28 days). In the pooled colorectal database the median duration of treatment was 139 days for capecitabine-treated patients and 140 days for 5-FU/LV-treated patients. A total of 78 (13%) and 63 (11%) capecitabine and 5-FU/LVtreated patients, respectively, discontinued treatment because of adverse reactions/intercurrent illness. A total of 82 deaths due to all causes occurred either on study or within 28 days of receiving study drug: 50 (8.4%) patients randomized to XELODA and 32 (5.4%) randomized to 5-FU/LV.
Table 6 Pooled Phase 3 Colorectal Trials : Percent Incidence of Adverse
Reactions in =5% of Patients
Adverse Event | XELODA (n=596) |
5-FU/LV (n=593) |
||||
Total % |
Grade 3% |
Grade 4% |
Total % |
Grade 3% |
Grade 4% |
|
Number of Patients With > One Adverse Event |
96 | 52 | 9 | 94 | 45 | 9 |
Body System/Adverse Event | ||||||
GI | ||||||
Diarrhea | 55 | 13 | 2 | 61 | 10 | 2 |
Nausea | 43 | 4 | - | 51 | 3 | <1 |
Vomiting | 27 | 4 | <1 | 30 | 4 | <1 |
Stomatitis | 25 | 2 | <1 | 62 | 14 | 1 |
Abdominal Pain | 35 | 9 | <1 | 31 | 5 | - |
Gastrointestinal Motility Disorder |
10 | <1 | - | 7 | <1 | - |
Constipation | 14 | 1 | <1 | 17 | 1 | - |
Oral Discomfort | 10 | - | - | 10 | - | - |
Upper GI Inflammatory Disorders |
8 | <1 | - | 10 | 1 | - |
Gastrointestinal Hemorrhage |
6 | 1 | <1 | 3 | 1 | - |
Ileus | 6 | 4 | 1 | 5 | 2 | 1 |
Skin and Subcutaneous | ||||||
Hand-and-Foot Syndrome |
54 | 17 | NA | 6 | 1 | NA |
Dermatitis | 27 | 1 | - | 26 | 1 | - |
Skin Discoloration | 7 | <1 | - | 5 | - | - |
Alopecia | 6 | - | - | 21 | <1 | - |
General | ||||||
Fatigue/Weakness | 42 | 4 | - | 46 | 4 | - |
Pyrexia | 18 | 1 | - | 21 | 2 | - |
Edema | 15 | 1 | - | 9 | 1 | - |
Pain | 12 | 1 | - | 10 | 1 | - |
Chest Pain | 6 | 1 | - | 6 | 1 | <1 |
Neurological | ||||||
Peripheral Sensory Neuropathy | 10 | - | - | 4 | - | - |
Headache | 10 | 1 | - | 7 | - | - |
Dizziness* | 8 | <1 | - | 8 | <1 | - |
Insomnia | 7 | - | - | 7 | - | - |
Taste Disturbance | 6 | 1 | - | 11 | <1 | 1 |
Metabolism | ||||||
Appetite Decreased | 26 | 3 | <1 | 31 | 2 | <1 |
Dehydration | 7 | 2 | <1 | 8 | 3 | 1 |
Eye | ||||||
Eye Irritation | 13 | - | - | 10 | <1 | - |
Vision Abnormal | 5 | - | - | 2 | - | - |
Respiratory | ||||||
Dyspnea | 14 | 1 | - | 10 | <1 | 1 |
Cough | 7 | <1 | 1 | 8 | - | - |
Pharyngeal Disorder | 5 | - | - | 5 | - | - |
Epistaxis | 3 | <1 | - | 6 | - | - |
Sore Throat | 2 | - | - | 6 | - | - |
Musculoskeletal | ||||||
Back Pain | 10 | 2 | - | 9 | <1 | - |
Arthralgia | 8 | 1 | - | 6 | 1 | - |
Vascular | ||||||
Venous Thrombosis | 8 | 3 | <1 | 6 | 2 | - |
Psychiatric | ||||||
Mood Alteration | 5 | - | - | 6 | <1 | - |
Depression | 5 | - | - | 4 | <1 | - |
Infections | ||||||
Viral | 5 | <1 | - | 5 | <1 | - |
Blood and Lymphatic | ||||||
Anemia | 80 | 2 | <1 | 79 | 1 | <1 |
Neutropenia | 13 | 1 | 2 | 46 | 8 | 13 |
Hepatobiliary | ||||||
Hyperbilirubinemia | 48 | 18 | 5 | 17 | 3 | 3 |
–Not observed NA = Not Applicable *Excluding vertigo |
Breast Cancer
In Combination With Docetaxel
The following data are shown for the combination study with XELODA and docetaxel in patients with metastatic breast cancer in Table 7 and Table 8. In the XELODA and docetaxel combination arm the treatment was XELODA administered orally 1250 mg/m2 twice daily as intermittent therapy (2 weeks of treatment followed by 1 week without treatment) for at least 6 weeks and docetaxel administered as a 1- hour intravenous infusion at a dose of 75 mg/m2 on the first day of each 3-week cycle for at least 6 weeks. In the monotherapy arm docetaxel was administered as a 1-hour intravenous infusion at a dose of 100 mg/m2 on the first day of each 3-week cycle for at least 6 weeks. The mean duration of treatment was 129 days in the combination arm and 98 days in the monotherapy arm. A total of 66 patients (26%) in the combination arm and 49 (19%) in the monotherapy arm withdrew from the study because of adverse reactions. The percentage of patients requiring dose reductions due to adverse reactions was 65% in the combination arm and 36% in the monotherapy arm. The percentage of patients requiring treatment interruptions due to adverse reactions in the combination arm was 79%. Treatment interruptions were part of the dose modification scheme for the combination therapy arm but not for the docetaxel monotherapy-treated patients.
Table 7 Percent Incidence of Adverse Events Considered Related or
Unrelated to Treatment in =5% of Patients Participating in the XELODA
and Docetaxel Combination vs Docetaxel Monotherapy Study
Adverse Event | XELODA 1250 mg/m2 /bid With Docetaxel 75 mg/m2 /3 weeks (n=251) |
Docetaxel 100 mg/m2 /3 weeks (n=255) |
||||
Total % |
Grade 3% |
Grade 4% |
Total % |
Grade 3% |
Grade 4% |
|
Number of Patients With at Least One Adverse Event |
99 | 76.5 | 29.1 | 97 | 57.6 | 31.8 |
Body System/Adverse Event | ||||||
GI | ||||||
Diarrhea | 67 | 14 | <1 | 48 | 5 | <1 |
Stomatitis | 67 | 17 | <1 | 43 | 5 | - |
Nausea | 45 | 7 | - | 36 | 2 | - |
Vomiting | 35 | 4 | 1 | 24 | 2 | - |
Constipation | 20 | 2 | - | 18 | - | - |
Abdominal Pain | 30 | <3 | <1 | 24 | 2 | - |
Dyspepsia | 14 | - | - | 8 | 1 | - |
Dry Mouth | 6 | <1 | - | 5 | - | - |
Skin and Subcutaneous | ||||||
Hand-and-Foot Syndrome |
63 | 24 | NA | 8 | 1 | NA |
Alopecia | 41 | 6 | - | 42 | 7 | - |
Nail Disorder | 14 | 2 | - | 15 | - | - |
Dermatitis | 8 | - | - | 11 | 1 | - |
Rash Erythematous | 9 | <1 | - | 5 | - | - |
Nail Discoloration | 6 | - | - | 4 | <1 | - |
Onycholysis | 5 | 1 | - | 5 | 1 | - |
Pruritus | 4 | - | - | 5 | - | - |
General | ||||||
Pyrexia | 28 | 2 | - | 34 | 2 | - |
Asthenia | 26 | 4 | <1 | 25 | 6 | - |
Fatigue | 22 | 4 | - | 27 | 6 | - |
Weakness | 16 | 2 | - | 11 | 2 | - |
Pain in Limb | 13 | <1 | - | 13 | 2 | - |
Lethargy | 7 | - | - | 6 | 2 | - |
Pain | 7 | <1 | - | 5 | 1 | - |
Chest Pain (non-cardiac) | 4 | <1 | - | 6 | 2 | - |
Influenza-like Illness | 5 | - | - | 5 | - | - |
Neurological | ||||||
Taste Disturbance | 16 | <1 | - | 14 | <1 | - |
Headache | 15 | 3 | - | 15 | 2 | - |
Paresthesia | 12 | <1 | - | 16 | 1 | - |
Dizziness | 12 | - | - | 8 | <1 | - |
Insomnia | 8 | - | - | 10 | <1 | - |
Peripheral Neuropathy | 6 | - | - | 10 | 1 | - |
Hypoaesthesia | 4 | <1 | - | 8 | <1 | - |
Metabolism | ||||||
Anorexia | 13 | 1 | - | 11 | <1 | - |
Appetite Decreased | 10 | - | - | 5 | - | - |
Weight Decreased | 7 | - | - | 5 | - | - |
Dehydration | 10 | 2 | - | 7 | <1 | <1 |
Eye | ||||||
Lacrimation Increased | 12 | - | - | 7 | <1 | - |
Conjunctivitis | 5 | - | - | 4 | - | - |
Eye Irritation | 5 | - | - | 1 | - | - |
Musculoskeletal | ||||||
Arthralgia | 15 | 2 | - | 24 | 3 | - |
Myalgia | 15 | 2 | - | 25 | 2 | - |
Back Pain | 12 | <1 | - | 11 | 3 | - |
Bone Pain | 8 | <1 | - | 10 | 2 | - |
Cardiac | ||||||
Edema | 33 | <2 | - | 34 | <3 | 1 |
Blood | ||||||
Neutropenic Fever | 16 | 3 | 13 | 21 | 5 | 16 |
Respiratory | ||||||
Dyspnea | 14 | 2 | <1 | 16 | 2 | - |
Cough | 13 | 1 | - | 22 | <1 | - |
Sore Throat | 12 | 2 | - | 11 | <1 | - |
Epistaxis | 7 | <1 | - | 6 | - | - |
Rhinorrhea | 5 | - | - | 3 | - | - |
Pleural Effusion | 2 | 1 | - | 7 | 4 | - |
Infections | ||||||
Oral Candidiasis | 7 | <1 | - | 8 | <1 | - |
Urinary Tract Infection | 6 | <1 | - | 4 | - | - |
Upper Respiratory Tract | 4 | - | - | 5 | 1 | - |
Vascular | ||||||
Flushing | 5 | - | - | 5 | - | - |
Lymphoedema | 3 | <1 | - | 5 | - | - |
Psychiatric | ||||||
Depression | 5 | - | - | 5 | 1 | - |
–Not observed NA = Not Applicable |
Table 8 Percent of Patients With Laboratory Abnormalities Participating
in the XELODA and Docetaxel Combination vs Docetaxel Monotherapy
Study
Adverse Event | XELODA 1250
mg/m2 /bid With Docetaxel 75 mg/m2 /3 weeks (n=251) |
Docetaxel
100 mg/m2 /3 weeks (n=255) |
||||
Body System/ Adverse Event |
Total % |
Grade
3 % |
Grade
4 % |
Total % |
Grade
3 % |
Grade
4 % |
Hematologic | ||||||
Leukopenia | 91 | 37 | 24 | 88 | 42 | 33 |
Neutropenia/ Granulocytopenia | 86 | 20 | 49 | 87 | 10 | 66 |
Thrombocytopenia | 41 | 2 | 1 | 23 | 1 | 2 |
Anemia | 80 | 7 | 3 | 83 | 5 | <1 |
Lymphocytopenia | 99 | 48 | 41 | 98 | 44 | 40 |
Hepatobiliary | ||||||
Hyperbilirubinemia | 20 | 7 | 2 | 6 | 2 | 2 |
Monotherapy
The following data are shown for the study in stage IV breast cancer patients who received a dose of 1250
The manifestations of acute overdose would include nausea, vomiting, diarrhea, gastrointestinal irritation and bleeding, and bone marrow depression. Medical management of overdose should include customary supportive medical interventions aimed at correcting the presenting clinical manifestations. Although no clinical experience using dialysis as a treatment for XELODA overdose has been reported, dialysis may be of benefit in reducing circulating concentrations of 5'-DFUR, a low– molecular-weight metabolite of the parent compound.
Single doses of XELODA were not lethal to mice, rats, and monkeys at doses up to 2000 mg/kg (2.4, 4.8, and 9.6 times the recommended human daily dose on a mg/m2 basis).
Absorption
Following oral administration of 1255 mg/m2 BID to cancer patients, capecitabine reached peak blood levels in about 1.5 hours (Tmax) with peak 5-FU levels occurring slightly later, at 2 hours. Food reduced both the rate and extent of absorption of capecitabine with mean C and AUC decreased by 60% and 35%, respectively. The Cmax and AUC0-8 of 5-FU were also reduced by food by 43% and 21%, respectively. Food delayed Tmax of both parent and 5-FU by 1.5 hours.
The pharmacokinetics of XELODA and its metabolites have been evaluated in about 200 cancer patients over a dosage range of 500 to 3500 mg/m2 /day. Over this range, the pharmacokinetics of XELODA and its metabolite, 5'-DFCR were dose proportional and did not change over time. The increases in the AUCs of 5'-DFUR and 5-FU, however, were greater than proportional to the increase in dose and the AUC of 5-FU was 34% higher on day 14 than on day 1. The interpatient variability in the Cmax and AUC of 5-FU was greater than 85%.
Distribution
Plasma protein binding of capecitabine and its metabolites is less than 60% and is not concentrationdependent. Capecitabine was primarily bound to human albumin (approximately 35%). XELODA has a low potential for pharmacokinetic interactions related to plasma protein binding.
Bioactivation And Metabolism
Capecitabine is extensively metabolized enzymatically to 5-FU. In the liver, a 60 kDa carboxylesterase hydrolyzes much of the compound to 5'-deoxy-5-fluorocytidine (5'-DFCR). Cytidine deaminase, an enzyme found in most tissues, including tumors, subsequently converts 5'-DFCR to 5'-DFUR. The enzyme, thymidine phosphorylase (dThdPase), then hydrolyzes 5'-DFUR to the active drug 5-FU. Many tissues throughout the body express thymidine phosphorylase. Some human carcinomas express this enzyme in higher concentrations than surrounding normal tissues. Following oral administration of XELODA 7 days before surgery in patients with colorectal cancer, the median ratio of 5-FU concentration in colorectal tumors to adjacent tissues was 2.9 (range from 0.9 to 8.0). These ratios have not been evaluated in breast cancer patients or compared to 5-FU infusion.
Metabolic Pathway of capecitabine to 5-FU
The enzyme dihydropyrimidine dehydrogenase hydrogenates 5-FU, the product of capecitabine metabolism, to the much less toxic 5-fluoro-5, 6-dihydro-fluorouracil (FUH2). Dihydropyrimidinase cleaves the pyrimidine ring to yield 5-fluoro-ureido-propionic acid (FUPA). Finally, β-ureidopropionase cleaves FUPA to a-fluoro-β-alanine (FBAL) which is cleared in the urine.
In vitro enzymatic studies with human liver microsomes indicated that capecitabine and its metabolites (5'-DFUR, 5'-DFCR, 5-FU, and FBAL) did not inhibit the metabolism of test substrates by cytochrome P450 isoenzymes 1A2, 2A6, 3A4, 2C19, 2D6, and 2E1.
Excretion
Capecitabine and its metabolites are predominantly excreted in urine; 95.5% of administered capecitabine dose is recovered in urine. Fecal excretion is minimal (2.6%). The major metabolite excreted in urine is FBAL which represents 57% of the administered dose. About 3% of the administered dose is excreted in urine as unchanged drug. The elimination half-life of both parent capecitabine and 5-FU was about 0.75 hour.
Effect Of Age, Gender, And Race On The Pharmacokinetics Of Capecitabine
A population analysis of pooled data from the two large controlled studies in patients with metastatic colorectal cancer (n=505) who were administered XELODA at 1250 mg/m2 twice a day indicated that gender (202 females and 303 males) and race (455 white/Caucasian patients, 22 black patients, and 28 patients of other race) have no influence on the pharmacokinetics of 5'-DFUR, 5-FU and FBAL. Age has no significant influence on the pharmacokinetics of 5'-DFUR and 5-FU over the range of 27 to 86 years. A 20% increase in age results in a 15% increase in AUC of FBAL.
Following oral administration of 825 mg/m2 capecitabine twice daily for 14 days, Japanese patients (n=18) had about 36% lower Cmax and 24% lower AUC for capecitabine than the Caucasian patients (n=22). Japanese patients had also about 25% lower Cmax and 34% lower AUC for FBAL than the Caucasian patients. The clinical significance of these differences is unknown. No significant differences occurred in the exposure to other metabolites (5'-DFCR, 5'-DFUR, and 5-FU).
Effect Of Hepatic Insufficiency
XELODA has been evaluated in 13 patients with mild to moderate hepatic dysfunction due to liver metastases defined by a composite score including bilirubin, AST/ALT and alkaline phosphatase following a single 1255 mg/m2 dose of XELODA. Both AUC0-8 and Cmax of capecitabine increased by 60% in patients with hepatic dysfunction compared to patients with normal hepatic function (n=14). The AUC0-8 and Cmax of 5-FU were not affected. In patients with mild to moderate hepatic dysfunction due to liver metastases, caution should be exercised when XELODA is administered. The effect of severe hepatic dysfunction on XELODA is not known.
Effect Of Renal Insufficiency
Following oral administration of 1250 mg/m2 capecitabine twice a day to cancer patients with varying degrees of renal impairment, patients with moderate (creatinine clearance = 30 to 50 mL/min) and severe (creatinine clearance <30 mL/min) renal impairment showed 85% and 258% higher systemic exposure to FBAL on day 1 compared to normal renal function patients (creatinine clearance >80 mL/min). Systemic exposure to 5'-DFUR was 42% and 71% greater in moderately and severely renal impaired patients, respectively, than in normal patients. Systemic exposure to capecitabine was about 25% greater in both moderately and severely renal impaired patients.
Effect Of Capecitabine On The Pharmacokinetics Of Warfarin
In four patients with cancer, chronic administration of capecitabine (1250 mg/m2 bid) with a single 20 mg dose of warfarin increased the mean AUC of S-warfarin by 57% and decreased its clearance by 37%. Baseline corrected AUC of INR in these 4 patients increased by 2.8-fold, and the maximum observed mean INR value was increased by 91%.
Effect Of Antacids On The Pharmacokinetics Of Capecitabine
When Maalox® (20 mL), an aluminum hydroxide- and magnesium hydroxide-containing antacid, was administered immediately after XELODA (1250 mg/m2 , n=12 cancer patients), AUC and Cmax increased by 16% and 35%, respectively, for capecitabine and by 18% and 22%, respectively, for 5'-DFCR. No effect was observed on the other three major metabolites (5'-DFUR, 5-FU, FBAL) of XELODA.
Effect Of Capecitabine On The Pharmacokinetics Of Docetaxel And Vice Versa
A Phase 1 study evaluated the effect of XELODA on the pharmacokinetics of docetaxel (Taxotere®) and the effect of docetaxel on the pharmacokinetics of XELODA was conducted in 26 patients with solid tumors. XELODA was found to have no effect on the pharmacokinetics of docetaxel (Cmax and AUC) and docetaxel has no effect on the pharmacokinetics of capecitabine and the 5-FU precursor 5'- DFUR.